Document Detail

A work in progress: the clinical development of histone deacetylase inhibitors.
MedLine Citation:
PMID:  18487953     Owner:  NLM     Status:  MEDLINE    
It has been widely recognized that histone deacetylases (HDAC) are promising targets in the field of oncology. An impressive body of preclinical research points to the ability of HDAC inhibitors (HDACIs) to modulate a wide variety of cellular functions, including cell differentiation, cell cycle progression, apoptosis, cytoskeletal modifications and angiogenesis. Originally developed as epigenetic drugs because of their ability to inhibit histones deacetylation, HDACIs are now being considered also because of their effects on other acetylation-regulated proteins with pivotal roles in transformed cells. This review will highlight the clinical development of HDACIs in oncology and will try to discuss the several major open clinical issues challenging the successful clinical development of HDACIs, with a particular emphasis on the spectrum of activity of these agents, the best development strategy in solid tumors, the cardiac side effects and bio-markers to be used in clinical trials.
Silvia Marsoni; Giovanna Damia; Gabriella Camboni
Related Documents :
2846273 - Early increase in histone h1(0) mrna during differentiation of f9 cells to parietal end...
16675713 - Antileukemia activity of the combination of an anthracycline with a histone deacetylase...
24239273 - Lobaplatin arrests cell cycle progression, induces apoptosis and alters the proteome in...
Publication Detail:
Type:  Journal Article; Review     Date:  2008-05-09
Journal Detail:
Title:  Epigenetics : official journal of the DNA Methylation Society     Volume:  3     ISSN:  1559-2308     ISO Abbreviation:  Epigenetics     Publication Date:    2008 May-Jun
Date Detail:
Created Date:  2008-07-16     Completed Date:  2008-10-02     Revised Date:  2010-01-15    
Medline Journal Info:
Nlm Unique ID:  101265293     Medline TA:  Epigenetics     Country:  United States    
Other Details:
Languages:  eng     Pagination:  164-71     Citation Subset:  IM    
SENDO Foundation, Milano, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / chemistry,  therapeutic use*
Clinical Trials as Topic
Enzyme Inhibitors / chemistry,  therapeutic use*
Histone Deacetylase Inhibitors*
Hydroxamic Acids
Neoplasms / drug therapy*,  enzymology
Reg. No./Substance:
0/Antineoplastic Agents; 0/Benzamides; 0/Enzyme Inhibitors; 0/Histone Deacetylase Inhibitors; 0/Hydroxamic Acids

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  "Targeting the absence" and therapeutic engineering for cancer therapy.
Next Document:  Suppression of p38-stress kinase sensitizes quiescent leukemic cells to anti-mitotic drugs by induci...